DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Johann S. de Bono, Emma Hall et al.|New England Journal of Medicine|2015Cited by 2.2k
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T. Williamson, Christopher J. Lord, Rowan Miller et al.|Nature Communications|2016Cited by 386
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivityIlirjana Bajrami, Alan Ashworth, Rowan Miller et al.|Cancer Research|2013Cited by 367
Functional Viability Profiles of Breast CancerRachel Brough, Alan Ashworth|Cancer Discovery|2011Cited by 143
Large-Scale Profiling of Kinase Dependencies in Cancer Cell LinesJames Campbell, Christopher J. Lord, Colm J. Ryan et al.|Cell Reports|2016Cited by 109